Related Stories
WP_Query Object ( [query] => Array ( [post_type] => post [posts_per_page] => 3 [post_status] => publish [orderby] => rand ) [query_vars] => Array ( [post_type] => post [posts_per_page] => 3 [post_status] => publish [orderby] => rand [error] => [m] => [p] => 0 [post_parent] => [subpost] => [subpost_id] => [attachment] => [attachment_id] => 0 [name] => [pagename] => [page_id] => 0 [second] => [minute] => [hour] => [day] => 0 [monthnum] => 0 [year] => 0 [w] => 0 [category_name] => [tag] => [cat] => [tag_id] => [author] => [author_name] => [feed] => [tb] => [paged] => 0 [meta_key] => [meta_value] => [preview] => [s] => [sentence] => [title] => [fields] => [menu_order] => [embed] => [category__in] => Array ( ) [category__not_in] => Array ( ) [category__and] => Array ( ) [post__in] => Array ( ) [post__not_in] => Array ( ) [post_name__in] => Array ( ) [tag__in] => Array ( ) [tag__not_in] => Array ( ) [tag__and] => Array ( ) [tag_slug__in] => Array ( ) [tag_slug__and] => Array ( ) [post_parent__in] => Array ( ) [post_parent__not_in] => Array ( ) [author__in] => Array ( ) [author__not_in] => Array ( ) [search_columns] => Array ( ) [ignore_sticky_posts] => [suppress_filters] => [cache_results] => 1 [update_post_term_cache] => 1 [update_menu_item_cache] => [lazy_load_term_meta] => 1 [update_post_meta_cache] => 1 [nopaging] => [comments_per_page] => 50 [no_found_rows] => [order] => ) [tax_query] => WP_Tax_Query Object ( [queries] => Array ( ) [relation] => AND [table_aliases:protected] => Array ( ) [queried_terms] => Array ( ) [primary_table] => wp_posts [primary_id_column] => ID ) [meta_query] => WP_Meta_Query Object ( [queries] => Array ( ) [relation] => [meta_table] => [meta_id_column] => [primary_table] => [primary_id_column] => [table_aliases:protected] => Array ( ) [clauses:protected] => Array ( ) [has_or_relation:protected] => ) [date_query] => [request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID FROM wp_posts WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish')) ORDER BY RAND() LIMIT 0, 3 [posts] => Array ( [0] => WP_Post Object ( [ID] => 4804 [post_author] => 4 [post_date] => 2025-03-20 12:10:54 [post_date_gmt] => 2025-03-20 16:10:54 [post_content] =>The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
Application Deadline: May 15, 2025, 5pm ET
Learn more about the program, get information session details and access the full request for proposals here: https://centerforbiotechnology.org/what-we-do/technology-development/reach/
[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards [post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => news-reach25 [to_ping] => [pinged] => [post_modified] => 2025-03-24 12:11:36 [post_modified_gmt] => 2025-03-24 16:11:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4804 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
Read the press release of Governor Hochul's announcement here:
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2025-02-26 16:35:20 [post_modified_gmt] => 2025-02-26 21:35:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 4389 [post_author] => 4 [post_date] => 2024-02-26 12:22:02 [post_date_gmt] => 2024-02-26 17:22:02 [post_content] =>
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapyThe Center for Biotechnology has announced a Call for Proposals for our 2024 Applied Research and Development (ARAD) Program. The ARAD program provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and NY State corporate partners in all areas of medical biotechnology.
These areas include research technologies, diagnostics, therapeutics and medical devices. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy.
2024 Proposal Submission:
The deadline for receipt of applications is May 15, 2024, 5pm. No exceptions will be made. Applications are accepted and considered on a competitive basis and are subject to the availability of funds. Approval from the Research Foundation Sponsored Programs is not required prior to submission, but will be required if the project is selected for funding. All applications require a letter-of-support from a senior executive of the company confirming their corporate residency in New York State and financial commitment to match-fund the project. Further details are found within the forms pages. A single PDF version of the proposal and letter of support should be submitted to the Center for Biotechnology at center_for_biotechnology@stonybrook.edu.ARAD Program Forms:
Call for Applications & Guidelines
[post_title] => Call for Proposals: Applied Research and Development Program 2024 [post_excerpt] => 2024 Applied Research and Development (ARAD) Program RFP Released! The ARAD program provides matching funds on a support collaborations between Stony Brook University faculty and NY State corporate partners. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => arad-2024 [to_ping] => [pinged] => [post_modified] => 2024-05-13 10:38:27 [post_modified_gmt] => 2024-05-13 14:38:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4389 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3000 [post_author] => 3 [post_date] => 2018-07-02 19:03:31 [post_date_gmt] => 2018-07-02 19:03:31 [post_content] => Boris Shor, one of the Center for Biotechnology’s newest BioEntrepreneurs-in-Residence, has earned a place for his start-up, Manhattan Biosolutions, in Johnson and Johnson Innovations latest facility, JLABS @ NYC, as one of four winners of the company’s prestigious QuickFire Challenge. The winners of the QuickFire Challenge receive one year of residence in JLABS @ NYC, which provides to a bench, workstation and the global JLABS community Manhattan BioSolutions’ lead platform is based on the safe, attenuated BCG bacteria targeting mutated cancer driver genes to induce innate and adaptive cancer-specific immune responses. Manhattan BioSolutions shares JLABS 30,000-square feet located at the New York Genome Center with 25 other companies. [post_title] => CFB BioEntreprenuer-in-Residence Earns Spot in New JLABS @ NYC [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => cfb-bioentreprenuer-in-residence-earns-spot-in-new-jlabs-nyc [to_ping] => [pinged] => [post_modified] => 2018-08-27 13:19:49 [post_modified_gmt] => 2018-08-27 13:19:49 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=3000 [menu_order] => 119 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [4] => WP_Post Object ( [ID] => 2552 [post_author] => 3 [post_date] => 2017-01-09 15:31:38 [post_date_gmt] => 2017-01-09 15:31:38 [post_content] => Sincerest congratulations to our clients who are being recognized among Stony Brook University's 40 under 40 for 2016. Since earning their Stony Brook degree, they have gone on to pursue their passions, help others and lead positive change. J. Robert Coleman ’08, PhD Molecular Genetics and Microbiology - Chief Operating Officer, Codagenix, Inc Katarzyna M. Sawicka ’04, ’05, ’14, BS Engineering Chemistry, MS Chemistry, PhD Biomedical Engineering - Founder and President, ImmunoMatrix Joseph Scaduto ’08, MBA Business Administration - Founder and CEO, Traverse Biosciences Inc.
Additionally, warmest wishes of continued success to Stony Brook's Director of Government Relations, Lauren Brookmeyer, who was recently named a Long Island Business News "40 under 40 Class of 2017" honoree. [post_title] => Congratulations 40 under 40 Winners! [post_excerpt] => Three Center for Biotech clients are among the talented individuals recognized as Stony Brook University 's 2016 "40 under 40". [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => congratulations-40-under-40-winners [to_ping] => [pinged] => [post_modified] => 2017-01-09 15:31:38 [post_modified_gmt] => 2017-01-09 15:31:38 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2552 [menu_order] => 155 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 5 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4804 [post_author] => 4 [post_date] => 2025-03-20 12:10:54 [post_date_gmt] => 2025-03-20 16:10:54 [post_content] =>
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
Application Deadline: May 15, 2025, 5pm ET
Learn more about the program, get information session details and access the full request for proposals here: https://centerforbiotechnology.org/what-we-do/technology-development/reach/
[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards [post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => news-reach25 [to_ping] => [pinged] => [post_modified] => 2025-03-24 12:11:36 [post_modified_gmt] => 2025-03-24 16:11:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4804 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 265 [max_num_pages] => 89 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )